Press Releases

Biothera to Present New Data at the American Society of Clinical Oncology Annual Meeting

EAGAN, MN — May 28, 2015 — Biothera announced today that new data and insights for Imprime PGG, the company’s investigational cancer immunotherapy drug, will be featured in four presentations at the 2015 American Society of Clinical Oncology annual meeting May 29-June 2 in Chicago. Saturday, May 30; 8:00 am-11:30 am. Location: S Hall A: Abstract #3070. Poster Board Number #396Durability and Characteristics of Objective...

Read More


Biothera to Present Additional Data to the American Association of Immunologists on Imprime PGG’s Potential to Alleviate Tumor-mediated Immunosuppression

NEW ORLEANS — May 8, 2015 — Additional data showing Biothera’s investigational cancer immunotherapy Imprime PGG can alleviate tumor-mediated immunosuppression and potentially strengthen the body’s ability to recognize and kill tumor cells will be presented on Sunday at the American Association of Immunologists (AAI) annual meeting. Earlier this month at the American Association for Cancer Research, Biothera presented new research supporting the potential of Imprime...

Read More


Biothera’s Investigational Cancer Immunotherapy Alleviates Immune Suppression by Regulatory T Cells, Enabling CD4 and CD8 T Cell Proliferation, Study Finds

New Data Presented at the American Association for Cancer Research Annual Meeting PHILADELPHIA — April 22, 2015 — Biothera’s investigational cancer immunotherapy Imprime PGG enhances the function and proliferation of T cells that play a critical role in the fight against cancer, according to new data presented today at the American Association for Cancer Research (AACR) annual meeting. “Cancer can create an immunosuppressive environment that...

Read More


New Data Demonstrate Potential of Biothera’s Investigational Cancer Immunotherapy to Re-orient the Tumor Microenvironment to Facilitate Greater Anti-Tumor Activity

Company to Present Four Scientific Posters at the American Association for Cancer Research Annual Meeting PHILADELPHIA – April 21, 2015 – Biothera is presenting new data today at the world’s largest meeting of cancer researchers that shows its investigational cancer immunotherapy drug Imprime PGG has the potential to initiate a coordinated anti-tumor response involving both the innate and adaptive immune systems. “Cancer often creates a...

Read More


Biothera’s Investigational Cancer Immunotherapy Drug Imprime PGG Elicits Dramatic Expansion of Cytotoxic T Cells

Late-Breaking Data Presented at the American Association for Cancer Research (AACR) Annual Meeting PHILADELPHIA – April 21, 2015 – Biothera researchers are presenting several studies at this year’s AACR meeting showing that treatment with its investigational immunotherapy Imprime PGG consistently triggers expansion of cytotoxic T cells (CD8+ T cells)—cells critically responsible for eradicating virally infected cells and for selectively killing cancer cells. A late-breaking research...

Read More


Biothera’s Imprime PGG Cancer Immunotherapy Drug Candidate Shows Potential to Enhance Efficacy of Immune Checkpoint Inhibitors

New Data on Imprime PGG’s Ability to Enhance Expression of PD-L1 on Tumor Cells Presented at the American Association for Cancer Research Annual Meeting PHILADELPHIA – April 21, 2015 – A scientific poster presented today during a late-breaking session at the American Association for Cancer Research (AACR) annual meeting showed that Biothera’s Imprime PGG investigational cancer immunotherapy may have the potential to enhance the efficacy...

Read More


Biothera’s Imprime PGG Investigational Immunotherapy Drug Modulates the Function of Macrophages and Dendritic Cells to Drive Expansion of Anti-cancer T Cells

Study Further Supports the Role of Imprime PGG in Triggering a Coordinated Immune Response PHILADELPHIA – April 21, 2015 – New research demonstrates that Imprime PGG, an investigational cancer immunotherapy drug in late-stage development by Biothera, modulates the function of key cells of the innate immune system—macrophages and dendritic cells—to drive expansion of T cells, which are critical for anti-cancer immunity. The results were reported...

Read More


Biothera Immunotherapy Combination Results in Tumor Reduction During Maintenance Phase of Non-Small Cell Lung Cancer Study

GENEVA — April 15, 2015 — The combination of the investigational cancer immunotherapy Imprime PGG and the monoclonal antibody bevacizumab achieved additional meaningful reductions in tumor burden during the maintenance phase of Biothera’s recent phase 2 clinical trial in non-small cell lung cancer (NSCLC). The new data will be released today at the European Lung Cancer Conference. Biothera conducted a randomized Phase 2 clinical study...

Read More


Biothera to Present Three Late-Breaking Posters at the American Association for Cancer Research Annual Meeting

EAGAN, MN — April 9, 2015 — Biothera scientists will present four scientific posters at the world’s largest annual cancer research conference: the American Association for Cancer Research (AACR) annual meeting April 18-22 in Philadelphia. Three of the posters were selected for the high profile, late-breaking research sessions—sessions devoted to the newest, most exciting research of the year. “We are excited to present the latest...

Read More


Biothera to Participate in Novel Immunomodulatory Therapies Panel Discussion at Cancer Progress Conference

EAGAN, MN — March 16, 2015 — Ada Braun, M.D., Ph.D., Chief Medical Officer for Biothera’s Pharmaceutical business, will participate in an expert panel discussion of novel immunomodulatory therapies tomorrow at the 26th Annual Cancer Progress Conference in New York, NY. The panel will include leading clinicians and researchers from major pharmaceutical companies focused on new therapies that engage the immune system to fight cancer....

Read More



Page 5 of 6« First...23456